Domov › Parkinsonova bolezen › Michigan › Farmington Hills

Klinične študije za Parkinsonova bolezen v Farmington Hills, MI

13 študij za Parkinsonova bolezen išče udeležence na lokacijah v Farmington Hills in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Vključevanje udeležencevFaza 2

Quest Research Institute, Farmington Hills

Starost 40–80 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06680830

A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease

Vključevanje udeležencevFaza 1Vabljeni zdravi prostovoljci

Quest Research Institute - Alcanza, Farmington Hills

Starost 30–80 · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06565195

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Vključevanje udeležencevFaza 2/3

Site-015, Farmington Hills

Starost 40–80 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06976268

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Vključevanje udeležencevFaza 2

Quest Research Institute, Farmington Hills

Starost 40–80 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07005180

A Study of Buntanetap in Participants With PD

Vključevanje udeležencevFaza 2/3

Quest Research Institute, Farmington Hills

Starost 40–85 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07284784

A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

Vključevanje udeležencevFaza 2

Vima Site #002, Farmington Hills

Starost 18–65 · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07804615

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Vključevanje udeležencevFaza 2

Quest Research Institute - Alcanza - PPDS (Site #201), Farmington Hills

Starost 30–80 · Vsi spoli · Posodobljeno 10. sep. 2026 · NCT07432958

A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations

Vključevanje udeležencevFaza 2

Quest Research Institute - Alcanza - HyperCore - PPDS, Farmington Hills

Starost 40–85 · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT07514858

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Vključevanje udeležencevFaza 3

Quest Research Institute, Farmington Hills

Starost 50–85 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07174310

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Vključevanje udeležencevFaza 3

Quest Research Institute, Farmington Hills

Starost 45–75 · Vsi spoli · Posodobljeno 4. avg. 2026 · NCT06944522

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

Vključevanje udeležencevFaza 1

Quest Research Institute, Farmington Hills

Starost 40–80 · Vsi spoli · Posodobljeno 5. jun. 2026 · NCT07422675

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Vključevanje udeležencevFaza 1Vabljeni zdravi prostovoljci

QUEST Research Institute, Farmington Hills

Starost 30–85 · Vsi spoli · Posodobljeno 20. apr. 2026 · NCT06809400

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Vključevanje udeležencevFaza 4

Quest Research Institute, Farmington Hills

Starost 18 in več · Vsi spoli · Posodobljeno 24. avg. 2025 · NCT06765668

Študije za Parkinsonova bolezen v drugih mestih

Druge študije v Farmington Hills

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.